Introduction
Non-alcoholic fatty liver disease (NAFLD) encompasses a variety of hepatic disorders, including steatosis, steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma [
1]. The global prevalence of NAFLD is 25.24%, with the highest rates related to the Middle East and South America [
2]. This disorder is also becoming one of the most common causes of liver transplantation [
3]. NAFLD is a hepatic manifestation of metabolic syndrome and is strongly associated with obesity, insulin resistance, type 2 diabetes mellitus, and dyslipidemia [
4]. Previous studies suggest that some dietary and lifestyle factors could influence NAFLD pathogenesis, prevention, and treatment [
5,
6].
Selenium is a trace mineral and an essential component of the active sites of several proteins, such as glutathione peroxidase, thioredoxin reductase, selenoprotein P, and iodothyronine deiodinase [
7,
8]. Therefore, this micronutrient participates in numerous body functions, including cell signaling systems, defending against free radicals, modulation of inflammatory responses, and immune and reproductive systems regulations [
7,
9]. There are two forms of selenium in nature and organisms. Selenomethionine and selenocysteine are organic, and selenide, selenite, selenate, and elemental selenium are inorganic forms [
8,
10]. The primary source of dietary selenium in humans is selenomethionine [
7]. The Recommended Dietary Allowance (RDA) for selenium is 55 µg/ day for adults [
11]. The amount of selenium in foods, especially plant-based foods, depends on the selenium content of the soil in a specific geographical area; therefore, dietary selenium intake varies significantly between countries. However, meat and dairy products, eggs, cereals, fish, poultry, seafood, and Brazil nuts are the main sources, and plants are the poor sources of selenium [
8].
There are conflicting epidemiological studies on the association between selenium and metabolic disorders. Higher selenium intake and blood levels have been associated with an elevated risk of diabetes [
12‐
16], hyperlipidemia [
17,
18], hypertension [
19], and NAFLD [
20,
21]. Nonetheless, some evidence suggested no or a negative association between selenium and the risk of NAFLD or diabetes [
22‐
24]. Therefore, due to the limited evidence and conflicting data, we aimed to perform the present cross-sectional study to investigate the association between dietary selenium intake and NAFLD in the general population of Kavar County.
Results
Table
1 shows the characteristics of the study participants by quintiles of dietary energy-adjusted selenium intake. The median age of the total study population was 45 years (minimum: 35, maximum: 70). Subjects in the highest quintile of energy-adjusted selenium intake were more likely to be male, Turk Nomad, to consume lower fiber, fructose, and saturated fatty acids, and to have lower age and higher physical activity, blood pressure, TG, ALT, AST, and GGT levels compared to those in the lowest quintile. Furthermore, participants with higher selenium intake had lower high-density and low-density lipoprotein cholesterol (HDL-C and LDL-C). The prevalence of NAFLD in the total population was 56.4% according to the FLI and 51.9% based on the HSI markers. The NAFLD prevalence was not significantly different between quintiles of selenium intake.
Table 1
Basic characteristics of the participants according to the quintiles of energy-adjusted selenium intake
n | 3026 | 605 | 605 | 605 | 606 | 605 | - |
Sex, n (%) | | | | | | | |
Male Female | 1716 (56.7) 1310 (43.3) | 317 (52.4) 288 (47.6) | 296 (48.9) 309 (51.1) | 306 (50.6) 299 (49.4) | 360 (59.4) 246 (40.6) | 437 (72.2) 168 (27.8) | < 0.001 |
Education, n (%) | | | | | | | |
Illiterate Elementary school Middle and high school College | 737 (24.4) 929 (30.7) 1043 (34.5) 317 (10.5) | 155 (25.6) 207 (34.2) 201 (33.2) 42 (6.9) | 156 (25.8) 193 (31.9) 194 (32.1) 62 (10.2) | 128 (21.2) 198 (32.7) 197 (32.6) 82 (13.6) | 171 (28.2) 164 (27.1) 211 (34.8) 60 (9.9) | 127 (21.0) 167 (27.6) 240 (39.7) 71 (11.7) | < 0.001 |
Ethnicity, n (%) | | | | | | | |
Persian Turk Nomad Others or mixed | 2290 (75.7) 621 (20.5) 115 (3.8) | 478 (79.0) 100 (16.5) 27 (4.5) | 470 (77.7) 109 (18.0) 26 (4.3) | 482 (79.7) 104 (17.2) 19 (3.1) | 441 (72.8) 136 (22.4) 29 (4.8) | 419 (69.3) 172 (28.4) 14 (2.3) | < 0.001 |
Smoking, n (%) | | | | | | | |
Non-smoker Ex-smoker Current smoker | 2212 (73.1) 220 (7.3) 594 (19.6) | 427 (70.6) 46 (7.6) 132 (21.8) | 467 (77.2) 27 (4.5) 111 (18.3) | 468 (77.4) 42 (6.9) 95 (15.7) | 440 (72.6) 46 (7.6) 120 (19.8) | 410 (67.8) 59 (9.8) 136 (22.5) | < 0.001 |
Alcohol intake, n (%) | | | | | | | |
No Yes | 2684 (88.7) 342 (11.3) | 531 (87.8) 74 (12.2) | 550 (90.9) 55 (9.1) | 558 (92.2) 47 (7.8) | 534 (88.1) 72 (11.9) | 511 (84.5) 94 (15.5) | < 0.001 |
Wealth score index, n (%) | | | | | | | |
1st quintile 2nd quintile 3rd quintile 4th quintile 5th quintile | 614 (20.3) 618 (20.4) 620 (20.5) 661 (21.8) 513 (17.0) | 106 (17.5) 120 (19.8) 115 (19.0) 153 (25.3) 111 (18.3) | 111 (18.3) 124 (20.5) 135 (22.3) 119 (19.7) 116 (19.2) | 106 (17.5) 114 (18.8) 117 (19.3) 142 (23.5) 126 (20.8) | 125 (20.6) 128 (21.1) 135 (22.3) 129 (21.3) 89 (14.7) | 166 (27.4) 132 (21.8) 118 (19.5) 118 (19.5) 71 (11.7) | < 0.001 |
Age (years), mean ± SD | 46.00 ± 8.17 | 47.08 ± 8.24 | 46.23 ± 8.10 | 45.89 ± 8.15 | 46.15 ± 8.46 | 44.66 ± 7.72 | < 0.001 |
BMI (kg/m2), mean ± SD | 26.67 ± 4.68 | 26.73 ± 4.96 | 26.55 ± 4.98 | 26.76 ± 4.46 | 26.67 ± 4.49 | 26.64 ± 4.50 | 0.947 |
Waist circumference (cm), mean ± SD | 93.92 ± 10.60 | 94.29 ± 11.21 | 93.88 ± 10.98 | 94.14 ± 10.43 | 93.76 ± 10.17 | 93.53 ± 10.22 | 0.744 |
Serum TC (mg/dl), mean ± SD | 174.81 ± 36.00 | 176.68 ± 34.27 | 173.40 ± 36.00 | 176.79 ± 35.41 | 175.07 ± 35.98 | 172.08 ± 38.08 | 0.095 |
Serum HDL-C (mg/dl), mean ± SD | 41.73 ± 9.17 | 42.33 ± 9.33 | 43.04 ± 9.23 | 41.72 ± 9.43 | 41.49 ± 9.11 | 40.07 ± 8.49 | < 0.001 |
Serum LDL-C (mg/dl), mean ± SD | 103.77 ± 29.56 | 106.34 ± 27.95 | 102.53 ± 30.07 | 106.06 ± 28.69 | 104.26 ± 29.80 | 99.64 ± 30.78 | < 0.001 |
Serum TG (mg/dl), median (range) | 123.00 (1408) | 119.00 (652) | 126.00 (900) | 126.00 (889) | 126.00 (709) | 133.00 (1408) | 0.004 |
FPG (mg/dl), median (range) | 93.00 (281) | 93.00 (279) | 92.00 (146) | 93.00 (214) | 93.00 (127) | 93.00 (272) | 0.863 |
ALT (U/L), median (range) | 17.00 (218) | 16.00 (95) | 16.00 (180) | 17.00 (204) | 18.00 (157) | 19.00 (215) | < 0.001 |
AST (U/L), median (range) | 17.00 (396) | 17.00 (57) | 16.00 (395) | 17.00 (77) | 17.00 (122) | 18.00 (174) | < 0.001 |
GGT (U/L), median (range) | 19.00 (370) | 19.00 (153) | 18.00 (143) | 18.00 (257) | 20.00 (161) | 21.00 (367) | < 0.001 |
SBP (mmHg), mean ± SD | 114.69 ± 13.24 | 114.00 ± 13.19 | 113.64 ± 13.77 | 114.60 ± 13.51 | 115.24 ± 13.11 | 115.98 ± 12.51 | 0.015 |
DBP (mmHg), mean ± SD | 75.48 ± 9.45 | 74.51 ± 9.42 | 74.78 ± 9.73 | 75.45 ± 9.46 | 75.79 ± 9.38 | 76.87 ± 9.11 | < 0.001 |
Activity level (MET-h/week), mean ± SD | 41.94 ± 6.91 | 41.67 ± 6.70 | 41.72 ± 6.33 | 41.92 ± 6.61 | 41.51 ± 6.59 | 42.86 ± 8.12 | 0.006 |
Dietary total energy intake (kcal/d), mean ± SD | 2247.02 ± 607.57 | 2414.00 ± 673.77 | 2134.43 ± 549.51 | 2127.85 ± 559.15 | 2154.81 ± 572.45 | 2404.19 ± 603.20 | < 0.001 |
Dietary SFA intake (g/day), mean ± SD | 19.03 ± 7.66 | 21.78 ± 9.21 | 18.84 ± 7.34 | 17.84 ± 6.78 | 17.82 ± 6.77 | 18.86 ± 7.25 | < 0.001 |
Dietary cholesterol intake (mg/day), mean ± SD | 234.30 ± 112.60 | 218.59 ± 97.56 | 213.19 ± 94.16 | 255.97 ± 104.93 | 236.49 ± 109.53 | 277.27 ± 139.53 | < 0.001 |
Dietary fiber intake (g/day), mean ± SD | 26.85 ± 9.58 | 30.12 ± 11.56 | 26.02 ± 9.04 | 25.58 ± 9.00 | 24.98 ± 8.39 | 27.56 ± 8.71 | < 0.001 |
Dietary fructose intake (g/day), mean ± SD | 30.34 ± 16.90 | 41.30 ± 22.15 | 31.34 ± 14.57 | 28.43 ± 14.23 | 25.66 ± 13.50 | 24.99 ± 12.94 | < 0.001 |
Dietary selenium intake (µg/day), mean ± SD | 109.29 ± 37.03 | 88.77 ± 30.49 | 93.73 ± 27.36 | 102.91 ± 27.91 | 114.48 ± 28.79 | 146.58 ± 38.13 | < 0.001 |
Dietary selenium intake (µg/kg/day), mean ± SD | 1.57 ± 0.55 | 1.29 ± 0.47 | 1.37 ± 0.42 | 1.49 ± 0.43 | 1.64 ± 0.46 | 2.04 ± 0.61 | < 0.001 |
NAFLD based on FLI, n (%) | 1708 (56.4) | 336 (55.5) | 323 (53.4) | 347 (57.4) | 350 (57.8) | 352 (58.2) | 0.424 |
NAFLD based on HSI, n (%) | 1570 (51.9) | 309 (51.1) | 297 (49.1) | 318 (52.6) | 323 (53.3) | 323 (53.4) | 0.526 |
The characteristics of the participants according to the NAFLD status are reported in Table
2. The NAFLD patients were more likely to be Persian, female, non-smoker, non-drinker, and have higher socioeconomic status than the healthy subjects. They also had higher BMI, waist circumference, blood pressure, TG, total cholesterol, LDL-C, FPG, ALT, AST, and GGT levels. Significant differences also were observed between patients with and without NAFLD regarding physical activity, HDL-C levels, and fiber and fructose intakes. These results were similar between FLI- and HSI-defined NAFLD, except that patients with HSI-defined NAFLD were significantly younger than healthy subjects (45.11 ± 7.45 vs. 46.97 ± 8.78,
P < 0.001).
Table 2
Basic characteristics of the NAFLD and non-NAFLD population
n (%) | 1708 (56.4) | 1318 (43.6) | - | 1570 (51.9) | 1456 (48.1) | - |
Sex, n (%) | | | | | | |
Male Female | 873 (51.1) 835 (48.9) | 843 (64.0) 475 (36.0) | < 0.001 | 715 (45.5) 855 (54.5) | 1001 (68.8) 455 (31.3) | < 0.001 |
Education, n (%) | | | | | | |
Illiterate Elementary school Middle and high school Academic degree | 415 (24.3) 531 (31.1) 570 (33.4) 192 (11.2) | 322 (24.14) 398 (30.2) 473 (35.9) 125 (9.5) | 0.289 | 371 (23.6) 484 (30.8) 545 (34.7) 170 (10.8) | 366 (25.1) 445 (30.6) 498 (34.2) 147 (10.1) | 0.761 |
Ethnicity, n (%) | | | | | | |
Persian Turk Nomad Others or mixed | 1325 (77.6) 317 (18.6) 66 (3.9) | 965 (73.2) 304 (23.1) 49 (3.7) | 0.01 | 1226 (78.1) 283 (18.0) 61 (3.9) | 1064 (73.1) 338 (23.2) 54 (3.7) | 0.002 |
Smoking, n (%) | | | | | | |
Non-smoker Ex-smoker Current smoker | 1338 (78.3) 117 (6.9) 253 (14.8) | 874 (66.3) 103 (7.8) 341 (25.9) | < 0.001 | 1292 (82.3) 96 (6.1) 182 (11.16) | 920 (63.2) 124 (8.5) 412 (28.3) | < 0.001 |
Alcohol intake | | | | | | |
No Yes | 1542 (90.3) 166 (9.7) | 1142 (86.6) 176 (13.4) | 0.002 | 1437 (91.5) 133 (8.5) | 1247 (85.6) 209 (14.4) | < 0.001 |
Wealth score index, n (%) | | | | | | |
1st quintile 2nd quintile 3rd quintile 4th quintile 5th quintile | 305 (17.9) 322 (18.9) 355 (20.8) 398 (23.3) 328 (19.2) | 309 (23.4) 296 (22.5) 265 (20.1) 263 (20.0) 185 (14.0) | < 0.001 | 299 (19.0) 279 (17.8) 334 (21.3) 358 (22.8) 300 (19.1) | 315 (21.6) 339 (23.3) 286 (19.6) 303 (20.8) 213 (14.6) | < 0.001 |
Age (years), mean ± SD | 45.93 ± 7.87 | 46.10 ± 8.54 | 0.573 | 45.11 ± 7.45 | 46.97 ± 8.78 | < 0.001 |
BMI (kg/m2), mean ± SD | 29.51 ± 3.74 | 22.98 ± 2.85 | < 0.001 | 29.87 ± 3.69 | 23.21 ± 2.81 | < 0.001 |
Waist circumference (cm), mean ± SD | 100.22 ± 8.43 | 85.76 ± 6.94 | < 0.001 | 100.52 ± 8.75 | 86.81 ± 7.33 | < 0.001 |
Serum TC (mg/dl), mean ± SD | 184.12 ± 35.98 | 162.73 ± 32.25 | < 0.001 | 181.82 ± 35.39 | 167.24 ± 35.10 | < 0.001 |
Serum HDL-C (mg/dl), mean ± SD | 40.38 ± 9.02 | 43.48 ± 9.07 | < 0.001 | 41.18 ± 9.13 | 42.32 ± 9.18 | 0.001 |
Serum LDL-C (mg/dl), mean ± SD | 107.71 ± 30.93 | 98.66 ± 26.85 | < 0.001 | 107.59 ± 30.28 | 99.65 ± 28.19 | < 0.001 |
Serum TG (mg/dl), median (range) | 154.50 (1381) | 93.00 (318) | < 0.001 | 140.00 (1387) | 106.00 (827) | < 0.001 |
FPG (mg/dl), median (range) | 94.00 (280) | 91.00 (79) | < 0.001 | 94.00 (273) | 91.00 (281) | < 0.001 |
ALT (U/L), median (range) | 20.00 (218) | 14.00 (132) | < 0.001 | 21.00 (216) | 14.00 (182) | < 0.001 |
AST (U/L), median (range) | 17.00 (396) | 16.00 (121) | < 0.001 | 17.00 (174) | 16.00 (395) | < 0.001 |
GGT (U/L), median (range) | 23.00 (367) | 16.00 (154) | < 0.001 | 22.00 (369) | 17.00 (160) | < 0.001 |
SBP (mmHg), mean ± SD | 117.23 ± 13.18 | 111.40 ± 12.59 | < 0.001 | 116.39 ± 12.50 | 112.86 ± 13.77 | < 0.001 |
DBP (mmHg), mean ± SD | 77.80 ± 9.07 | 72.47 ± 9.09 | < 0.001 | 77.34 ± 8.90 | 73.47 ± 9.62 | < 0.001 |
Activity level (MET-h/week), mean ± SD | 41.38 ± 6.38 | 42.66 ± 7.49 | < 0.001 | 41.39 ± 6.14 | 42.52 ± 7.62 | < 0.001 |
Dietary total energy intake (kcal/d), mean ± SD | 2252.09 ± 606.00 | 2240.46 ± 609.78 | 0.602 | 2242.42 ± 613.61 | 2251.99 ± 601.16 | 0.665 |
Dietary SFA intake (g/day), mean ± SD | 18.85 ± 7.38 | 19.26 ± 8.00 | 0.146 | 18.87 ± 7.50 | 19.20 ± 7.82 | 0.225 |
Dietary cholesterol intake (mg/day), mean ± SD | 232.62 ± 109.78 | 236.48 ± 116.15 | 0.350 | 231.94 ± 110.09 | 236.85 ± 115.23 | 0.231 |
Dietary fiber intake (g/day), mean ± SD | 27.39 ± 9.68 | 26.15 ± 9.40 | < 0.001 | 27.38 ± 9.89 | 26.28 ± 9.20 | 0.002 |
Dietary fructose intake (g/day), mean ± SD | 31.17 ± 16.94 | 29.28 ± 16.80 | 0.002 | 31.01 ± 17.29 | 29.62 ± 16.45 | 0.024 |
Dietary selenium intake (µg/day), mean ± SD | 110.03 ± 37.54 | 108.35 ± 36.34 | 0.215 | 109.43 ± 37.76 | 109.15 ± 36.23 | 0.838 |
The association between dietary energy-adjusted selenium intake and NAFLD risk is demonstrated in Table
3. As shown in model 1 (crude ORs), the relationship between selenium intake and NAFLD risk was non-significant in both NAFLD prediction models. After adjustment for age, sex, ethnicity, education levels, smoking status, alcohol intake, WSI, and physical activity (model 2), the adjusted OR and 95% CIs for FLI- and HSI- defined NAFLD comparing the fifth quintile of selenium intake with reference group were 1.42 (1.11–1.80) and 1.40 (1.09–1.79), respectively, with a progressive increase in risk across quintiles (
P trend < 0.05).
Table 3
Risk of NAFLD according to the quintiles of energy-adjusted selenium intake (µg/day)
Event/Total | 336/605 | 323/605 | 347/605 | 350/606 | 352/605 | |
†Model 1, OR (95%CI) | 1.00 (Ref.) | 0.92 (0.73–1.15) | 1.08 (0.86–1.35) | 1.09 (0.87–1.37) | 1.11 (0.89–1.40) | 0.160 |
‡Model 2, OR (95%CI) | 1.00 (Ref.) | 0.90 (0.71–1.13) | 1.05 (0.83–1.32) | 1.18 (0.93–1.49) | 1.42 (1.11–1.80) | 0.001 |
§Model 3, OR (95%CI) | 1.00 (Ref.) | 0.98 (0.77–1.25) | 1.15 (0.90–1.48) | 1.31 (1.01–1.70) | 1.50 (1.13–1.99) | 0.002 |
NAFLD assessed by HSI
|
Event/Total | 309/605 | 297/605 | 318/605 | 323/606 | 323/605 | |
†Model 1, OR (95%CI) | 1.00 (Ref.) | 0.92 (0.74–1.16) | 1.06 (0.85–1.33) | 1.09 (0.87–1.37) | 1.10 (0.88–1.37) | 0.336 |
‡Model 2, OR (95%CI) | 1.00 (Ref.) | 0.86 (0.67–1.09) | 0.98 (0.77–1.25) | 1.18 (0.93–1.50) | 1.40 (1.09–1.79) | 0.003 |
§Model 3, OR (95%CI) | 1.00 (Ref.) | 0.95 (0.74–1.22) | 1.11 (0.86–1.43) | 1.34 (1.03–1.75) | 1.50 (1.12–2.01) | 0.006 |
After adjusting for energy, saturated fatty acids, cholesterol, fiber, and fructose intakes (model 3), the multivariable-adjusted ORs and 95% CIs for FLI-defined NAFLD were 0.98 (0.77–1.25), 1.15 (0.90–1.48), 1.31 (1.01–1.70), and 1.50 (1.13–1.99) from the second to the fifth dietary selenium quintile, respectively, compared to the lowest category (
P trend = 0.002). Furthermore, the multivariable-adjusted ORs and 95% CIs for HSI-defined NAFLD from the second to the fifth quintile were 0.95 (0.74–1.22), 1.11 (0.86–1.43), 1.34 (1.03–1.75), and 1.50 (1.12–2.01), respectively (
P trend = 0.006) (Table
3).
Discussion
We conducted a population-based cross-sectional study in a large sample of Kavar County with the primary objective of assessing the relationship between dietary selenium intake and NAFLD prevalence. Our results demonstrated a weak positive linear association between dietary selenium intake and NAFLD risk. The prevalence rates of NAFLD in our population were 56.4% and 51.9%, based on the FLI and HSI markers, respectively. In our study, the mean selenium intake (109.29 µg/day) was higher than the RDA level as well as its intake by other Iranian populations [
33]. Moreover, all subjects consumed below the tolerance limits (400 µg/day), and only 3.4% ingested less than the RDA level for selenium intake.
In our study, participants with the highest selenium intake had 50% higher NAFLD risk after adjustment for major confounders. Limited epidemiological investigations have explored the association between selenium and NAFLD prevalence. Liu et al. detected a positive association between more than 121.90 µg/d selenium intake and the odds of steatosis [
34]. In another study of 8550 Chinese adults, participants in the third and fourth quartiles of plasma selenium levels had a 72% and 54% increased NAFLD risk compared with those in the reference quartile [
20]. Inconsistent with our findings, Wu et al. revealed a positive dose-response relationship between dietary selenium intake, below the recommendations, and the prevalence of NAFLD, detected by ultrasonography, in the general population of China [
21]. In another cross-sectional study of 42 adults with NAFLD, a negative and null correlation between selenium intake and liver fat was observed in females and males, respectively [
23]. This conflicting evidence could be due to the differences in the population, method of exposure assessment, amounts of selenium intake, method of NAFLD diagnosis, and considered confounding variables.
Many observational investigations demonstrated a positive association between dyslipidemia and diabetes risk with different selenium levels [
14,
15,
35,
36]. Insulin resistance and dyslipidemia have fundamental roles in NAFLD development and progression [
37]. Therefore, high dietary selenium intake may increase NAFLD risk by dysregulating insulin biosynthesis and secretion and stimulating glucagon secretion, insulin resistance, and dyslipidemia [
38]. The increment of liver protein tyrosine phosphatase 1B activity, an enzyme antagonizing insulin signaling and stimulating fatty acid synthesis, is also reported following selenium supplementation [
39]. Furthermore, the high intake of this trace element increased hepatic TG by upregulating gluconeogenesis and lipogenesis and downregulating lipolysis in pigs [
40]. However, more studies are warranted to clarify other related mechanisms.
Early detection of NAFLD may be helpful for the recognition of those with probably silent progressive NAFLD. Diagnostic routes are different and include clinical, biochemical, and radiographic tests. The liver biopsy remains the gold standard for NAFLD confirmation, but it is practically infeasible as a diagnostic instrument [
41]. In our study, NAFLD was predicted by computing FLI and HSI biomarkers. These validated indicators can be used for detecting participants to be referred for lifestyle counseling, ultrasonography, and conducting epidemiologic studies [
30,
31]. According to the study by Hsu et al., FLI was a stronger predictor than sex, liver function tests, BMI, body fat, FPG, uric acid, and triglyceride for NAFLD diagnosis in lean patients [
42]. In a previous study, a good agreement between NAFLD prevalence by FLI (47.6%) and HSI (53.5%) vs. controlled attenuation parameter derived via transient elastography (CAP-TE) (48.1%) was detected [
43]. However, a higher NAFLD prevalence was reported in studies using FLI than ultrasound in obese and diabetic patients [
44]. The NAFLD prevalence rates in our studied population were 56.4% and 51.9%, based on the FLI and HSI markers, respectively. These estimations were higher than the prevalence of ultrasonography or liver biopsy-diagnosed NAFLD in Iran (33.95%), yielded by a meta-analysis study published in 2016 [
45]. Therefore, differences in NAFLD diagnosis methods and increased incidence of NAFLD in recent years could partly describe the high prevalence of NAFLD in the present study.
The population-based sampling, large sample size, and assessing the association between selenium and NAFLD in the Iranian population for the first time are some strengths of the present study. Nonetheless, there are several limitations. First, due to the specific characteristics of the cross-sectional studies, supposing a causal connection between dietary selenium intake and NAFLD prevalence is impossible. Second, we used FLI and HSI markers but not liver biopsy as the gold standard of NAFLD diagnosis. Third, we did not assess the blood selenium concentration, which provides more reliable evidence regarding selenium’ status in the body. Using FFQ for selenium intake estimation in the current study may cause recall bias and errors in exposure assessment. Fourth, because of the social stigma associated with alcohol consumption in Iranian society, the actual amount of alcohol intake may be biased. Further well-designed prospective cohort studies on the association between blood serum biomarkers and NAFLD risk should be carried out to clarify this association.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.